Alethia Young - Graphite Bio Chief Officer

GRPHDelisted Stock  USD 2.67  0.05  1.84%   

Insider

Alethia Young is Chief Officer of Graphite Bio
Age 45
Phone650 484 0886
Webhttps://graphitebio.com

Graphite Bio Management Efficiency

The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5195) %, meaning that it created substantial loss on money invested by shareholders. Graphite Bio's management efficiency ratios could be used to measure how well Graphite Bio manages its routine affairs as well as how well it operates its assets and liabilities.
Graphite Bio currently holds 362 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Graphite Bio has a current ratio of 26.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Graphite Bio's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Bronson CrouchInstil Bio
51
Timothy MooreInstil Bio
63
Kim BlickenstaffNuvation Bio
68
DPHIL DPhilCytomX Therapeutics
57
Iraj AliAchilles Therapeutics PLC
49
Robert MDSensei Biotherapeutics
58
Steven FullerSensei Biotherapeutics
N/A
BSc FRCPathAchilles Therapeutics PLC
59
CPA CPANextCure
61
Solomon LangermannNextCure
64
Christopher OgdenCytomX Therapeutics
40
Kerry WentworthNuvation Bio
51
Hoyoung MDCytomX Therapeutics
55
David HanleyNuvation Bio
54
Michelle DoigNuvation Bio
46
Elisabeth ColunioSensei Biotherapeutics
N/A
Timothy MayerNextCure
59
David MDNuvation Bio
54
FMEDSCI MDAchilles Therapeutics PLC
49
Adam ZlotnickAssembly Biosciences
N/A
Thomas TemplemanNuvation Bio
60
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Graphite Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people. Graphite Bio (GRPH) is traded on NASDAQ Exchange in USA and employs 6 people.

Management Performance

Graphite Bio Leadership Team

Elected by the shareholders, the Graphite Bio's board of directors comprises two types of representatives: Graphite Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Graphite. The board's role is to monitor Graphite Bio's management team and ensure that shareholders' interests are well served. Graphite Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Graphite Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Stephanie Yao, Vice Relations
Maria MD, Academic Board
Christine PMP, Chief Operations
Jerry Cacia, Chief Officer
Philip Gutry, Chief Officer
Jane Grogan, Chief Officer
MD FACC, CEO Pres
Daniel Dever, CoFounder Research
Alethia Young, Chief Officer
Kimberlee CPA, CEO and Presidentident
Matthew MD, Academic Director

Graphite Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Graphite Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in Graphite Stock

If you are still planning to invest in Graphite Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Graphite Bio's history and understand the potential risks before investing.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Stocks Directory
Find actively traded stocks across global markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency